# Verrica Pharmaceuticals Inc.: overview VRCA · Nasdaq · CIK 1660334 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vrca.md) · [Financials](/companies/vrca/financials.md) · [Filings](/companies/vrca/filings.md) · [Insiders](/companies/vrca/insiders.md) Latest reported revenue: [$5.9m](/filings/0001660334-26-000025.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001660334-26-000025). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [(1.8)](/filings/0000950170-24-120982.md) | [0.3 d](/filings/0000950170-25-037172.md) | [3.4](/filings/0000950170-25-070452.md) | [12.7](/filings/0000950170-25-107358.md) | [14.3](/filings/0001660334-25-000006.md) | [5.1 d](/filings/0001660334-26-000008.md) | [5.0](/filings/0001660334-26-000014.md) | [5.9](/filings/0001660334-26-000025.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [1162.5%](/filings/0001660334-25-000006.md) | [(3316.9%) d](/filings/0001660334-26-000008.md) | [(236.4%)](/filings/0001660334-26-000014.md) | [11.9%](/filings/0001660334-26-000025.md) | [11.3%](/filings/0001660334-25-000006.md) | [(141.2%) d](/filings/0001660334-26-000008.md) | [(193.4%)](/filings/0001660334-26-000014.md) | [(223.4%)](/filings/0001660334-26-000025.md) | | Net margin | % | [1283.5%](/filings/0001660334-25-000006.md) | [(4709.9%) d](/filings/0001660334-26-000008.md) | [(283.3%)](/filings/0001660334-26-000025.md) | [1.6%](/filings/0001660334-26-000025.md) | [(1.9%)](/filings/0001660334-25-000006.md) | [(158.6%) d](/filings/0001660334-26-000008.md) | [(192.8%)](/filings/0001660334-26-000025.md) | [(224.4%)](/filings/0001660334-26-000025.md) | | Diluted EPS | $ per share | [(4.88)](/filings/0001660334-25-000006.md) | not reported | [(1.03)](/filings/0001660334-26-000014.md) | [0.02](/filings/0001660334-26-000025.md) | [(0.03)](/filings/0001660334-25-000006.md) | not reported | [(0.45)](/filings/0001660334-26-000014.md) | [(0.62)](/filings/0001660334-26-000025.md) | | Free cash flow | $m | [(8.6) d](/filings/0001660334-25-000006.md) | [(16.1) d](/filings/0001660334-26-000008.md) | not reported | not reported | [9.7 d](/filings/0001660334-25-000006.md) | [(4.6) d](/filings/0001660334-26-000008.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.0](/filings/0000950170-23-006118.md) | [9.0](/filings/0000950170-24-022659.md) | [5.1](/filings/0000950170-25-037172.md) | [7.6](/filings/0000950170-25-037172.md) | [35.6](/filings/0001660334-26-000008.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(257.6%)](/filings/0000950170-23-006118.md) | [(235.8%)](/filings/0000950170-24-022659.md) | [(1283.4%)](/filings/0000950170-25-037172.md) | [(871.3%)](/filings/0001660334-26-000008.md) | [(34.2%)](/filings/0001660334-26-000008.md) | | Net margin | % | [(292.3%)](/filings/0000950170-23-006118.md) | [(271.1%)](/filings/0000950170-24-022659.md) | [(1307.5%)](/filings/0000950170-25-037172.md) | [(1012.1%)](/filings/0001660334-26-000008.md) | [(50.3%)](/filings/0001660334-26-000008.md) | | Diluted EPS | $ per share | [(1.30)](/filings/0000950170-23-006118.md) | [(0.72)](/filings/0000950170-24-022659.md) | [(1.48)](/filings/0000950170-25-037172.md) | [(14.78)](/filings/0001660334-26-000008.md) | [(1.68)](/filings/0001660334-26-000008.md) | | Free cash flow | $m | [(28.5)](/filings/0000950170-23-006118.md) | [(19.0)](/filings/0000950170-24-022659.md) | [(38.9)](/filings/0000950170-25-037172.md) | [(61.0)](/filings/0001660334-26-000008.md) | [(17.6)](/filings/0001660334-26-000008.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vrca/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $5.7m | 923,910 | | Unchanged | | [CANNELL CAPITAL LLC](/funds/1058854.md) | 2026-06-30 | $4.8m | 783,923 | | Added +98,800 | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $4.3m | 707,338 | | Unchanged | | [Velan Capital Investment Management LP](/funds/1848809.md) | 2026-06-30 | $2.9m | 471,559 | | Unchanged | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $2.6m | 426,304 | | Reduced −91,877 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $1.7m | 280,734 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.7m | 279,310 | | Added +90,552 | | [Mariner, LLC](/funds/1373442.md) | 2026-06-30 | $1.3m | 207,230 | | Added +182,686 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $845.7k | 138,160 | | Reduced −757 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $455.0k | 74,344 | | Added +35,791 | ## Recent filings [All 534 filings](/companies/vrca/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 16:37 ET | [10-Q](/filings/0001660334-26-000025.md) | Quarterly report, period 2026-06-30 | 0001660334-26-000025 | | 2026-08-06 | 16:34 ET | [8-K](/filings/0001193125-26-338273.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338273 | | 2026-06-09 | 16:05 ET | [8-K](/filings/0001193125-26-263722.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-263722 | | 2026-05-12 | 16:15 ET | [10-Q](/filings/0001660334-26-000014.md) | Quarterly report, period 2026-03-31 | 0001660334-26-000014 | | 2026-05-12 | 16:07 ET | [8-K](/filings/0001193125-26-219395.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219395 | | 2026-04-20 | 16:10 ET | [DEF 14A](/filings/0001193125-26-163961.md) | Proxy statement, period 2026-06-05 | 0001193125-26-163961 | | 2026-03-11 | 08:11 ET | [10-K](/filings/0001660334-26-000008.md) | Annual report, period 2025-12-31 | 0001660334-26-000008 | | 2026-03-11 | 08:08 ET | [8-K](/filings/0001193125-26-101126.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-101126 | | 2025-12-30 | 07:10 ET | [SCHEDULE 13D/A](/filings/0000902664-25-005417.md) | Ownership report, active investor, amended | 0000902664-25-005417 | | 2025-12-30 | 06:05 ET | [8-K](/filings/0001193125-25-335824.md) | 5.02 Departure or appointment of officers or directors | 0001193125-25-335824 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001660334-26-000008.md), filed Mar 11, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1e43f5ab-4850-4e3b-a615-f2cc19120be8) ## About the filer - CIK: 1660334 - Tickers: VRCA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.